EcoDrugPlus

Cystic Fibrosis Transmembrane Conductance Regulator-Like

Ensembl ID : ENSSTUG00000008374
Gene Symbol: LOC115152318
3 Cross references
210 Possible Orthologues:

Cystic Fibrosis Transmembrane Conductance Regulator-Like

Ensembl ID : ENSSTUG00000038250
Gene Symbol: LOC115197540
3 Cross references
210 Possible Orthologues:

Cytidine Deaminase A

Ensembl ID : ENSSTUG00000019378
Gene Symbol: CDAA
1 Cross references
150 Possible Orthologues:

Cytidine Deaminase B

Ensembl ID : ENSSTUG00000009913
Gene Symbol: CDAB
1 Cross references
194 Possible Orthologues:

Cytidine Deaminase-Like

Ensembl ID : ENSSTUG00000030408
Gene Symbol: LOC115151061
3 Cross references
196 Possible Orthologues:

Cytidine Deaminase-Like

Ensembl ID : ENSSTUG00000035802
Gene Symbol: LOC115165627
3 Cross references
151 Possible Orthologues:

Cytochrome P450 26a1-Like

Ensembl ID : ENSSTUG00000037674
Gene Symbol: LOC115181285
3 Cross references
193 Possible Orthologues:

Cytochrome P450 26a1-Like

Ensembl ID : ENSSTUG00000034923
Gene Symbol: LOC115189545
3 Cross references
193 Possible Orthologues:

Cytochrome P450 3a27

Ensembl ID : ENSSTUG00000018883
Gene Symbol: LOC115178672
3 Cross references
523 Possible Orthologues:

Cytochrome P450 3a27-Like

Ensembl ID : ENSSTUG00000021362
Gene Symbol: LOC115178488
3 Cross references
528 Possible Orthologues:

Cytochrome P450 3a27-Like

Ensembl ID : ENSSTUG00000020583
Gene Symbol: LOC115178487
3 Cross references
521 Possible Orthologues:

Cytochrome P450 3a27-Like

Ensembl ID : ENSSTUG00000019422
Gene Symbol: LOC115178667
3 Cross references
528 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).